Artificial Intelligence in Skin Cancer Diagnosis: A Reality Check.

The field of skin cancer detection offers a compelling use case for the application of artificial intelligence (AI) within the realm of image-based diagnostic medicine. Through the analysis of large datasets, AI algorithms have the capacity to classify clinical or dermoscopic images with remarkable accuracy. Although these AI-based applications can operate both autonomously and under human supervision, the best results are achieved through a collaborative approach that leverages the expertise of both AI and human experts. However, it is important to note that most studies focus on assessing the diagnostic accuracy of AI in artificial settings rather than in real-world scenarios. Consequently, the practical utility of AI-assisted diagnosis in a clinical environment is still largely unknown. Furthermore, there exists a knowledge gap concerning the optimal use cases and deployment settings for these AI systems as well as the practical challenges that may arise from widespread implementation. This review explores the advantages and limitations of AI in a variety of real-world contexts, with a specific focus on its value to consumers, general practitioners, and dermatologists.

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest AB has served on the advisory board and received honoraria for lectures and/or research grants for Amgen, Abbvie, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Lilly, Novartis, and UCB. JM is a cofounder of Athena Tech. SP declares serving as a speaker for Almirall, BMS, Cantabria, ISDIN, La Roche Posay, Leo Pharma, MSD, Novartis, Pfizer, Roche, Regeneron, Sanofi, and Sunpharma; serving on the advisory board for Almirall, BMS, ISDIN, La Roche Posay, Leo Pharma, Novartis, Pfizer, Regeneron, Roche, Sanofi, and Sun Pharma; research and trials for Abbvie, Almirall, Amgen, BMS, Biofrontera, Canfield, Cantabria, Fotofinder, GSK, ISDIN, La Roche Posay, Leo Pharma, MSD, MEDA, Novartis, Polychem, Roche, and Sun Phaarma; and spouse interests in Almirall, Amgen, BMS, Biofrontera, Canfield, Cantabria, Fotofinder, GSK, ISDIN, La Roche Posay, Leo, Mavig, Nevisence, Novartis, Polychem, Roche, and Sun Pharma. Other declarations are educational activities for Abbie and Lilly, ISD, and Athena Tech & Dermavision Solutions. HK received speaker honorariums from Fotofinder; equipment from Fotofinder, Heine, 3-Gen, DermaMedical, and Casio; and license fees from MetaOptima, Casio, and Heine.